Vesuvius (VSVS) Q2 2026 Earnings Report

The call presented a predominantly positive strategic and financial picture: strong cash generation, improved leverage, clear recovery in the Foundry division (MMS integration success), ongoing structural cost savings ahead of plan, and favorable structural steel market dynamics outside China. These positives were partially offset by identifiable short-term operational disruptions (US supplier/maintenance issues and India ramp-up) and pricing pressure in European Advanced Refractories, which depressed near-term performance by an estimated single-digit millions and created temporary market-share and revenue timing effects. Management communicated concrete remediation actions with timelines (resolution expected by year-end and structural benefits into 2027), supporting confidence in longer-term targets (including 12.5% margin ambition). On balance, the highlights (cash, deleveraging, Foundry strength, cost savings, innovation and favorable market trends) outweigh the transitory lowlights tied to operational issues and regional pricing pressure.

Vesuvius guided that full‑year 2026 trading profit should be slightly ahead of 2025 on a constant‑currency basis, supported by resolution of H1 operational issues (Steel Division H1 impact ~£8m — c.£6m US + c.£2m India — expected to abate through H2 and disappear by 2027) and a structurally improving steel market (steel production ex China/Russia/Iran/Ukraine +3.8% H1); H1 metrics include revenue +1.5% cc, trading profit £74m (broadly flat y/y cc), return on sales down ~10bp, headline EPS 16.3p (‑0.7% cc) and an interim dividend of 7.1p; financial guidance/targets include an underlying tax rate of ~27% for ’26 and beyond, FY26 capex increased to £75–80m, year‑end leverage to remain around 2x (net debt/EBITDA ~1.9 pro forma), H1 free cash flow +£41.4m to £27.5m with cash conversion 81% (vs 33% prior), working‑capital intensity down from 23.6% to 23.1% (long‑term target 21%), and structural cost savings of £7.4m in H1 with a minimum £55m target by 2028 (FY26 cash cost to achieve £10–12m; H1 non‑cash impairments £10.4m).